53 results
8-K
EX-10.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
prior to the date that this representation is made.
(k) Litigation. There is no Action which (i) adversely affects or challenges the legality … or penalty in any criminal or governmental litigation or proceeding under any provision of the Foreign Corrupt Practices Act of 1977, as amended.
(gg) Off
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may … and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated … on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure
8-K
EX-99.1
988twi
23 Oct 23
Other Events
11:12am
8-K
EX-99.1
rk7 lf3gezd6
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
EX-99.1
adc8ptk5q8avtn88gw5
14 Aug 23
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
9:19pm
8-K
EX-99.1
qpbdx 5oiy
29 Jun 23
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
5:50pm
8-K
EX-99.1
e6uo mcqq50khjg
16 May 23
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
10:30am
8-K
EX-99.1
kziyhaggd
31 Mar 23
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
8c2plewhl24d0r6e
29 Dec 22
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
12:55pm
8-K
EX-99.1
ul7vjy1p6
28 Dec 22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
9:29am
8-K
EX-99.1
rq4lks7r9 imtyc1mz
14 Nov 22
Unicycive Announces Third Quarter Financial Results and Provides Business Update
9:49am
S-3
EX-1.1
rwo 5fmd0wlbq
15 Aug 22
Shelf registration
6:20pm